Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
JAMA Network Open
|
December 8, 2022
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
Alexander S Watson, Siddhartha Goutam, Igor Stukalin, et al.
JTO Clinical and Research Reports
|
April 24, 2023
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors
Daniel E Meyers, Meghann Pasternak, Samantha Dolter, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 20, 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Paul Wheatley-Price, Vishal Navani, Aliyah Pabani, et al.
Clinical Lung Cancer
|
February 11, 2023
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade
Vishal Navani, Daniel E Meyers, Yibing Ruan, et al.
Current Oncology (Toronto, Ont.)
|
May 24, 2024
New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices
David J Stewart, John-Peter Bradford, Sandeep Sehdev, et al.
The Oncologist
|
April 3, 2023
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Igor Stukalin, Vishal Navani, Mehul Gupta, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations
Tejas Patil, Dexiang Gao, Alexander Watson, et al.
Internal Medicine Journal
|
May 28, 2021
Business as unusual: medical oncology services adapt and deliver during COVID-19
Avraham Travers, Kim Adler, Gillian Blanchard, et al.
Clinical Genitourinary Cancer
|
August 9, 2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Vishal Navani, J Connor Wells, Devon J Boyne, et al.
European Urology Oncology
|
January 1, 2025
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis
Mehul Gupta, Connor Wells, Meredith M Regan, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
JAMA Network Open
|
December 8, 2022
Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
Alexander S Watson, Siddhartha Goutam, Igor Stukalin, et al.
JTO Clinical and Research Reports
|
April 24, 2023
Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors
Daniel E Meyers, Meghann Pasternak, Samantha Dolter, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 20, 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Paul Wheatley-Price, Vishal Navani, Aliyah Pabani, et al.
Clinical Lung Cancer
|
February 11, 2023
Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade
Vishal Navani, Daniel E Meyers, Yibing Ruan, et al.
Current Oncology (Toronto, Ont.)
|
May 24, 2024
New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices
David J Stewart, John-Peter Bradford, Sandeep Sehdev, et al.
The Oncologist
|
April 3, 2023
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Igor Stukalin, Vishal Navani, Mehul Gupta, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations
Tejas Patil, Dexiang Gao, Alexander Watson, et al.
Internal Medicine Journal
|
May 28, 2021
Business as unusual: medical oncology services adapt and deliver during COVID-19
Avraham Travers, Kim Adler, Gillian Blanchard, et al.
Clinical Genitourinary Cancer
|
August 9, 2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Vishal Navani, J Connor Wells, Devon J Boyne, et al.
European Urology Oncology
|
January 1, 2025
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis
Mehul Gupta, Connor Wells, Meredith M Regan, et al.
Page
of 4